Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, ...
Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, April 21, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...
Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...
Gain Therapeutics has set its sights on proving the effectiveness of its Parkinson’s disease therapy next year after the brain-penetrant small molecule demonstrated “peripheral target engagement” in a ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, No. 16 (April 19, 2022), pp. 1-10 (10 pages) Allosteric modulators of G-protein-coupled receptors (GPCRs) ...
Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...
ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, ...
In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by ...
Addex Therapeutics’ GABAB PAM candidate shows robust anti-tussive activity in non-human primate chronic cough model: Geneva, Switzerland Wednesday, April 22, 2026, 18:00 Hrs [IS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results